1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Market Access Impact (EU5) [PsO]

Market Access Impact (EU5) [PsO]

  • March 2017
  • ID: 4833559
  • Format: PDF
  • By Firstword Pharma


Table of Contents


Eliminating market barriers could lift the last place brand into the middle of the pack
In the EU5 countries, market barriers affect nearly a quarter of psoriasis prescriptions. Most of the brands we surveyed gain or lose a little bit of market share, but one brand is having a much harder time of it. If it can find a way to overcome market barriers, this brand could climb from dead last to somewhere in the middle of the pack.

Find out whether breaking down market barriers can give your brand a boost in Market Access Impact: Psoriasis (EU5).

Based on a survey of 150 dermatologists, the report covers 10 major therapies from AbbVie, Biogen, Celgene, EliLilly, Janssen Cilag, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways
- Barriers have a modest effect on surveyed brands: They affect nearly a quarter of prescriptions, but no surveyed brand gains or loses more than 2 percent of its share because of them.
- “Other” brands see significant benefits: In aggregate, brands not surveyed see the largest barrier-related gain, putting them ahead of more than a third of surveyed brands.
- Barriers are holding the last-place brand down: If barriers didn’t exist, the last-place brand would climb to the middle of the pack.
- The barrier effect is uneven: Several barriers have a big effect on a small number of brands, and less of an effect on the rest.
- Many doctors don’t experience barriers at all: 40 percent or more of surveyed doctors don’t experience any barriers with most of the surveyed brands.
- Several brands have perception problems: 14 to 24 percent of surveyed doctors either wouldn’t consider prescribing them or simply don’t know they exist.

Insight into 10 Major Psoriasis Drugs
- Benepali (etanercept; Biogen)
- Cosentyx (secukinumab; Novartis)
- Enbrel (etanercept; Pfizer)
- Humira (adalimumab; AbbVie)
- Inflectra (infliximab; Pfizer)
- Otezla (apremilast; Celgene)
- Remicade (infliximab; Merck Sharp & Dohme)
- Remsima (infliximab; Napp/Mundipharma)
- Stelara (ustekinumab; Janssen Cilag)
- Taltz (ixekizumab; Eli Lilly)

Exploring Important Market Access Issues
Market Access Impact: Psoriasis (EU5) explores key issues affecting drug manufacturers.

You’ll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?

How barriers affect your brand:
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge
We surveyed 150 dermatologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with psoriasis in total in the last month

We conducted the survey between February 1st and 7th, 2017.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020

RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020SummaryRAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC ...

Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019

Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019SummaryCyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Facto ...

Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019SummaryCyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC - Cyclin-dependent kinase 4 is an enzyme encoded ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on